- Home
- Share
- Forum
- General forums
- Research and useful tips - Type 2 Diabetes
- Diabetes: Switching to common drugs raises risk of complications
Diabetes: Switching to common drugs raises risk of complications
- 88 views
- 1 support
- 5 comments
All comments
Unregistered member
'Finds that switching to a class of drugs called sulfonylureas could raise the risk of complications for people living with type 2 diabetes'. If this is the case that further complications are know then doctors should not prescribe them unless it is a 'last chance' scenario. Us diabetics have enough problems to think about as it is.
Surely knowing the possible added side effects, the drugs should not even be considered as an addition or replacement if the current medication regime is working? There are enough conditions around that can cause cardiovascular problems without adding to the list.
robjmckinney
AmbassadorGood advisor
robjmckinney
Ambassador
Last activity on 05/11/2024 at 19:23
Joined in 2015
591 comments posted | 109 in the Research and useful tips - Type 2 Diabetes group
46 of their responses were helpful to members
Rewards
-
Good Advisor
-
Contributor
-
Messenger
-
Committed
-
Explorer
-
Evaluator
One of the side effects of metformin is extended life expectancy a consultant assured me. She stated whatever happens keep up with my metformin and I will get a few extra years so always ensure I take it whatever other drugs I get added!
See the signature
robjmckinney
Bobcaz
Good advisor
Bobcaz
Last activity on 20/03/2023 at 17:06
Joined in 2016
26 comments posted | 4 in the Research and useful tips - Type 2 Diabetes group
1 of their responses was helpful to members
Rewards
-
Good Advisor
-
Contributor
-
Explorer
That is ok but many can not take metformin because of alwful sde efets
See the signature
R brown
Bobcaz
Good advisor
Bobcaz
Last activity on 20/03/2023 at 17:06
Joined in 2016
26 comments posted | 4 in the Research and useful tips - Type 2 Diabetes group
1 of their responses was helpful to members
Rewards
-
Good Advisor
-
Contributor
-
Explorer
Sorry side effects
See the signature
R brown
Unregistered member
'One of the side effects of Metformin is extended life expectancy.....' I've not heard that one.
I think I'll do some research and get back to you.
Richard
Give your opinion
Articles to discover...
04/11/2024 | News
21/10/2024 | News
Common health issues in pregnant women: Everything you need to know!
19/10/2024 | Nutrition
Turmeric: The golden source of anti-inflammatory and antioxidant benefits
12/10/2024 | News
12/11/2019 | Procedures & paperwork
21/01/2015 | News
14/10/2016 | News
Opioids Causing Concerns, Problems for Chronic Pain Patients
21/10/2014 | News
Subscribe
You wish to be notified of new comments
Your subscription has been taken into account
Margarita_k
Community managerGood advisor
Margarita_k
Community manager
Last activity on 07/10/2020 at 11:39
Joined in 2016
1,195 comments posted | 76 in the Research and useful tips - Type 2 Diabetes group
1 of their responses was helpful to members
Rewards
Good Advisor
Contributor
Messenger
Committed
Explorer
Evaluator
A new study, published in the journal BMJ, finds that switching to a class of drugs called sulfonylureas could raise the risk of complications for people living with type 2 diabetes.
Researchers set out to investigate how safe it is for patients with type 2 diabetes to switch from taking metformin, which is a standard "first-line" antidiabetic drug, to taking sulfonylureas, often prescribed to control blood sugar levels when metformin alone fails.
They were led by Prof. Samy Suissa, from McGill University in Quebec, Canada.
As Prof. Suissa and colleagues explain in their paper, numerous studies have confirmed the safety of sulfonylureas.
Fewer, however, have focused on their safety when patients have switched to the drugs or when they have added them to their previous treatment.
So, to fill this research gap, the scientists examined whether adding sulfonylureas or switching to them from metformin raises the risk of cardiovascular problems such as heart attack or stroke, or the risk of death from cardiovascular problems or from any other causes.
Also, the team examined whether or not switching to, or adding, sulfonylureas raised the risk of severe hypoglycemia, or low blood sugar. All these risks were compared with taking metformin alone.
Continuing metformin safer than switching
In order to study these links, the researchers examined over 77,138 people with type 2 diabetes who started taking metformin between 1998 and 2013.
Of these, 25,699 either added sulfonylureas to their treatment or switched to them altogether during the study period.
The team compared these people with age-matched controls who continued to take only metformin over a follow-up period of 1.1 years, on average.
Overall, when compared with staying on metformin, the study found that adding, or switching to, sulfonylureas was linked with a higher risk of a heart attack, death from any causes, and severe hypoglycemia.
More specifically, people adding, or switching to, the second-line treatment were 26 percent more likely to have a heart attack, 28 percent more likely to die from any causes, and over seven times more likely to have severe hypoglycemia, on average.
The researchers also discovered a trend toward a higher likelihood of stroke and death from heart problems in those switching to, or adding, sulfonylureas.
Finally, when comparing just adding sulfonylureas to metformin with switching to sulfonylureas completely, the latter raised the risk of a heart attack by 51 percent and mortality from all causes by 23 percent.
However, no differences were found in the risk of stroke, cardiovascular death, or hypoglycemia between just adding the drugs and switching to them.
Prof. Suissa and colleagues conclude, "Sulfonylureas as second-line drugs are associated with an increased risk of myocardial infarction, all-cause mortality, and severe hypoglycemia, compared with remaining on metformin monotherapy."
As with any observational study, causality cannot be inferred from the results. But researchers Lucy D'Agostino McGowan and Christianne Roumie deem the study "well designed and the relations [...] strong and consistent" in an accompanying editorial, which is also published in the BMJ.
Medical News Today